Literature DB >> 7912830

Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity.

W G Gutheil1, M Subramanyam, G R Flentke, D G Sanford, E Munoz, B T Huber, W W Bachovchin.   

Abstract

The human immunodeficiency virus 1 (HIV-1) Tat protein suppresses antigen-induced, but not mitogen-induced, activation of human T cells when added to T-cell cultures [Viscidi, R. P., Mayur, K., Lederman, H. M. & Frankel, A. D. (1989) Science 246, 1606-1608]. This activity is potentially pertinent to the development of AIDS because lymphocytes from HIV-infected individuals exhibit a similar antigen-specific dysfunction. Here we report that Tat binds with high affinity to the T-cell activation molecule dipeptidyl aminopeptidase IV (DP IV), also known as CD26. This molecule occurs on the surface of CD4+ cells responsible for the recall antigen response and appears to play an essential role in this response. Tat binds to both the cell surface and soluble forms of DP IV at physiological salt concentrations without inhibiting the protease activity of DP IV against small chromogenic substrates used to assay activity, but Tat markedly inhibits the activity of DP IV at lower salt concentrations. The kinetics of inhibition indicate the affinity of Tat for DP IV varies from 20 pM to 11 nM, and the activity of the Tat-DP IV complex varies from 13% to 100%, as the NaCl concentration varies from 0 to 140 mM. Cytofluorometry experiments demonstrate that Tat competes with anti-Ta1, a monoclonal antibody (mAb) specific for DP IV, for binding to cell surface DP IV, thus indicating that Tat binds DP IV at or near the Ta1 epitope. Moreover, the anti-Ta1 mAb blocks the immunosuppressive activity of Tat. The high affinity of Tat for DP IV, previous evidence implicating DP IV in antigen-specific T-cell activation events, and the ability of anti-Ta1 mAb to block the immunosuppressive effect of Tat make DP IV a plausible receptor for Tat's immunosuppressive activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7912830      PMCID: PMC44249          DOI: 10.1073/pnas.91.14.6594

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  The trans-activator gene of the human T cell lymphotropic virus type III is required for replication.

Authors:  A I Dayton; J G Sodroski; C A Rosen; W C Goh; W A Haseltine
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

2.  Bioassay for trans-activation using purified human immunodeficiency virus tat-encoded protein: trans-activation requires mRNA synthesis.

Authors:  R Gentz; C H Chen; C A Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

3.  Isolation and characterization of dipeptidyl aminopeptidase IV from human kidney cortex.

Authors:  G B Wolf; J E Scherberich; P Fischer; W Schoeppe
Journal:  Clin Chim Acta       Date:  1989-01-13       Impact factor: 3.786

4.  Antigen reactive memory T cells are defined by Ta1.

Authors:  D A Hafler; D A Fox; D Benjamin; H L Weiner
Journal:  J Immunol       Date:  1986-07-15       Impact factor: 5.422

Review 5.  The human immunodeficiency virus: infectivity and mechanisms of pathogenesis.

Authors:  A S Fauci
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

6.  Reactivity of E. coli-derived trans-activating protein of human T lymphotropic virus type III with sera from patients with acquired immune deficiency syndrome.

Authors:  A D Barone; J J Silva; D D Ho; R C Gallo; F F Wong-Staal; N T Chang
Journal:  J Immunol       Date:  1986-07-15       Impact factor: 5.422

7.  Mechanisms of immune memory. T cell activation and CD3 phosphorylation correlates with Ta1 (CDw26) expression.

Authors:  D A Hafler; M Chofflon; D Benjamin; N H Dang; J Breitmeyer
Journal:  J Immunol       Date:  1989-04-15       Impact factor: 5.422

8.  A transcriptional activator protein encoded by the x-lor region of the human T-cell leukemia virus.

Authors:  J Sodroski; C Rosen; W C Goh; W Haseltine
Journal:  Science       Date:  1985-06-21       Impact factor: 47.728

9.  Cyclophilin residues that affect noncompetitive inhibition of the protein serine phosphatase activity of calcineurin by the cyclophilin.cyclosporin A complex.

Authors:  F A Etzkorn; Z Y Chang; L A Stolz; C T Walsh
Journal:  Biochemistry       Date:  1994-03-08       Impact factor: 3.162

10.  Isolation and characterization of dipeptidyl peptidase IV from human placenta.

Authors:  G Püschel; R Mentlein; E Heymann
Journal:  Eur J Biochem       Date:  1982-08
View more
  36 in total

1.  Tat-neutralizing antibodies in vaccinated macaques.

Authors:  Ilia Tikhonov; Tracy J Ruckwardt; Glen S Hatfield; C David Pauza
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  HIV-1 Tat enters T cells using coated pits before translocating from acidified endosomes and eliciting biological responses.

Authors:  Agnès Vendeville; Fabienne Rayne; Anne Bonhoure; Nadir Bettache; Philippe Montcourrier; Bruno Beaumelle
Journal:  Mol Biol Cell       Date:  2004-03-12       Impact factor: 4.138

3.  Identification of specific molecular structures of human immunodeficiency virus type 1 Tat relevant for its biological effects on vascular endothelial cells.

Authors:  S Mitola; R Soldi; I Zanon; L Barra; M I Gutierrez; B Berkhout; M Giacca; F Bussolino
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Enzymatic properties of dipeptidyl aminopeptidase IV produced by the periodontal pathogen Porphyromonas gingivalis and its participation in virulence.

Authors:  Y Kumagai; K Konishi; T Gomi; H Yagishita; A Yajima; M Yoshikawa
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

5.  Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15.

Authors:  T Yamabe; K Takakura; K Sugie; Y Kitaoka; S Takeda; Y Okubo; K Teshigawara; J Yodoi; T Hori
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

6.  CD4⁺CD73⁺ T cells are associated with lower T-cell activation and C reactive protein levels and are depleted in HIV-1 infection regardless of viral suppression.

Authors:  Patrick J Schuler; Bernard J C Macatangay; Zenichiro Saze; Edwin K Jackson; Sharon A Riddler; William G Buchanan; Benedict B Hilldorfer; John W Mellors; Theresa L Whiteside; Charles R Rinaldo
Journal:  AIDS       Date:  2013-06-19       Impact factor: 4.177

7.  Successful immunomodulating in AIDS patients with ursodeoxycholic acid--a pilot study.

Authors:  D Kurktschiev; T Temelkova-Kurktschiev; K Horn; K Schentke
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

8.  Human endothelial cells enhance human immunodeficiency virus type 1 replication in CD4+ T cells in a Nef-dependent manner in vitro and in vivo.

Authors:  Jaehyuk Choi; Jason Walker; Sergei Boichuk; Nancy Kirkiles-Smith; Nicholas Torpey; Jordan S Pober; Louis Alexander
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

9.  Heterologous expression and purification of Vibrio proteolyticus (Aeromonas proteolytica) aminopeptidase: a rapid protocol.

Authors:  Mariam Hartley; Wei Yong; Brian Bennett
Journal:  Protein Expr Purif       Date:  2009-02-20       Impact factor: 1.650

10.  Noninfectious X4 but not R5 human immunodeficiency virus type 1 virions inhibit humoral immune responses in human lymphoid tissue ex vivo.

Authors:  Wendy Fitzgerald; Andrew W Sylwester; Jean-Charles Grivel; Jeffrey D Lifson; Leonid B Margolis
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.